SensoDetect publishes Q&A and gives update of current projects
Idag, 15:40
SensoDetect publishes Q&A and gives update of current projects
Malmö, 9 December 2025: The MedTech AI company SensoDetect AB (publ) today publishes a Q&A to give an update of ongoing projects and provide clarity. The Q&A is based on questions from investors and aim to provide a thorough overview as well as an insight into the company and the strategy forward.
- Our main focus is that our investors and the public feel confident with SensoDetect as a company. We hope that the Q&A will provide clarity and reassurance that progress is being made and that projects are advancing. If there are any additional or complementary questions, we are happy to answer them during a live Q&A next Monday, 15 December at 12.00 CET. We have scheduled the session during lunch break as we would like to give as many as possible the chance to join, says PA Hedin, CEO at SensoDetect, who also emphasizes that the company’s communication will be more concise and transparent moving forward.
Q&A key highlights include:
- 2026 will most likely be the year when commercial revenue becomes more visible, this due to the progressing of the clinical programs, JV licensing structures being activated, AI development has a defined plan and initial license payments have been confirmed.
- The AI engine is currently being integrated across global pilot programs. Each BERA test generates up to 7,200 structured signal images with 256 datapoints each, enabling the AI to apply the same advanced pattern-recognition methods that have driven modern AI’s explosive development. This creates a powerful foundation for improved clinical precision, scalability and future biomarker discovery. The new AI architecture enhances robustness, speed and demographic consistency, supporting high-volume screening models. Full validated performance metrics will be published following clinical and regulatory review.
- A new screening strategy where SensoDetect provides a complete method, AI platform and training is currently being rolled out. In the first stage of the roll out, this will primarily be available for private schools and private companies with a wider launch to be expected.
The Q&A can be found found here. This link to the live Q&A will be active once the event starts, on 15 December at 12.00 CET. The event will be held in English and hosted by PA Hedin and Dr Mohamed Atwa, Global Head of Clinical Research at SensoDetect.
SensoDetect AB is a MedTech AI company listed on the Spotlight Stock Market, focused on establishing the global standard for objective neuro-auditory brain screening. The company’s technology is based on more than 30 years of research in clinical psychoacoustics and neuroscience from Lund University and is protected by a strong international patent portfolio.
SensoDetect’s core platform uses brainstem auditory response patterns to objectively measure neural function in minutes. The method supports large-scale screening and clinical decision-making in conditions such as ADHD, autism spectrum disorder and other neurodevelopmental and psychiatric conditions—providing measurable signals where traditional diagnostic tools rely heavily on subjective assessment.
In recent years, the company has advanced from research to commercial deployment through strategic partnerships and clinical programs in Europe, the Middle East, and China. The latest generation of the system, including BERA 4.2 and integrated AI analysis, enables faster testing, greater scalability, and the ability to support national-level screening initiatives in healthcare, schools, and preventive medicine.
SensoDetect’s mission is to increase diagnostic accuracy, reduce waiting times, and support healthcare systems in managing the rapidly growing global need for mental and neurodevelopmental health evaluation. The company aims to make objective brain screening accessible at scale—improving outcomes for patients, families, and society.
More info at https://www.sensodetect.com/
For more information or partnership inquiries, please contact:
PA Hedin, CEO Sensodetect AB
+46 (0)46 15 79 04
pa.hedin@sensodetect.com
Ämnen i artikeln
SensoDetect publishes Q&A and gives update of current projects
Idag, 15:40
SensoDetect publishes Q&A and gives update of current projects
Malmö, 9 December 2025: The MedTech AI company SensoDetect AB (publ) today publishes a Q&A to give an update of ongoing projects and provide clarity. The Q&A is based on questions from investors and aim to provide a thorough overview as well as an insight into the company and the strategy forward.
- Our main focus is that our investors and the public feel confident with SensoDetect as a company. We hope that the Q&A will provide clarity and reassurance that progress is being made and that projects are advancing. If there are any additional or complementary questions, we are happy to answer them during a live Q&A next Monday, 15 December at 12.00 CET. We have scheduled the session during lunch break as we would like to give as many as possible the chance to join, says PA Hedin, CEO at SensoDetect, who also emphasizes that the company’s communication will be more concise and transparent moving forward.
Q&A key highlights include:
- 2026 will most likely be the year when commercial revenue becomes more visible, this due to the progressing of the clinical programs, JV licensing structures being activated, AI development has a defined plan and initial license payments have been confirmed.
- The AI engine is currently being integrated across global pilot programs. Each BERA test generates up to 7,200 structured signal images with 256 datapoints each, enabling the AI to apply the same advanced pattern-recognition methods that have driven modern AI’s explosive development. This creates a powerful foundation for improved clinical precision, scalability and future biomarker discovery. The new AI architecture enhances robustness, speed and demographic consistency, supporting high-volume screening models. Full validated performance metrics will be published following clinical and regulatory review.
- A new screening strategy where SensoDetect provides a complete method, AI platform and training is currently being rolled out. In the first stage of the roll out, this will primarily be available for private schools and private companies with a wider launch to be expected.
The Q&A can be found found here. This link to the live Q&A will be active once the event starts, on 15 December at 12.00 CET. The event will be held in English and hosted by PA Hedin and Dr Mohamed Atwa, Global Head of Clinical Research at SensoDetect.
SensoDetect AB is a MedTech AI company listed on the Spotlight Stock Market, focused on establishing the global standard for objective neuro-auditory brain screening. The company’s technology is based on more than 30 years of research in clinical psychoacoustics and neuroscience from Lund University and is protected by a strong international patent portfolio.
SensoDetect’s core platform uses brainstem auditory response patterns to objectively measure neural function in minutes. The method supports large-scale screening and clinical decision-making in conditions such as ADHD, autism spectrum disorder and other neurodevelopmental and psychiatric conditions—providing measurable signals where traditional diagnostic tools rely heavily on subjective assessment.
In recent years, the company has advanced from research to commercial deployment through strategic partnerships and clinical programs in Europe, the Middle East, and China. The latest generation of the system, including BERA 4.2 and integrated AI analysis, enables faster testing, greater scalability, and the ability to support national-level screening initiatives in healthcare, schools, and preventive medicine.
SensoDetect’s mission is to increase diagnostic accuracy, reduce waiting times, and support healthcare systems in managing the rapidly growing global need for mental and neurodevelopmental health evaluation. The company aims to make objective brain screening accessible at scale—improving outcomes for patients, families, and society.
More info at https://www.sensodetect.com/
For more information or partnership inquiries, please contact:
PA Hedin, CEO Sensodetect AB
+46 (0)46 15 79 04
pa.hedin@sensodetect.com
Ämnen i artikeln
Analyser
Inflationen
Aktierekommendationer
Mest läst
Analyser
Inflationen
Aktierekommendationer
Marknadsöversikt
1 DAG %
Senast
1 mån
